Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Algos completes full NDA filing for MorphiDex

Aug. 27, 1998

Adding SIB-1508Y to antiparkinsonian therapy allows for reduction in dose of L-dopa

Aug. 27, 1998

SSRI produces significant improvements in patients with social phobia

Aug. 26, 1998

Parke-Davis synthesizes potent and selective D4 ligands with antipsychotic potential

Aug. 26, 1998

Allelix research into antimigraine compounds proves fruitful

Aug. 26, 1998

Neuroprotective glutamate receptor antagonists disclosed by Warner-Lambert

Aug. 26, 1998

Dual 5-HT reuptake inhibitors/5-HT1A antagonists with potential as antidepressants

Aug. 26, 1998

Pagoclone reduces frequency of panic attacks in patients with panic disorder

Aug. 26, 1998

Disappointing results obtained in phase II/III trial of LU-25-109T

Aug. 25, 1998

Bristol-Myers Squibb discovers novel maxi-K channel openers

Aug. 25, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...